北方药学
北方藥學
북방약학
JOURNAL OF NORTH PHARMACY
2014年
7期
94-94,95
,共2页
肿瘤患者%SPAG9%外周血%自身抗体
腫瘤患者%SPAG9%外週血%自身抗體
종류환자%SPAG9%외주혈%자신항체
Cancer patients%SPAG9%Peripheral blood%Autoantibodies
目的：通过对肿瘤患者血清中抗原9（SPAG9）的自身抗体的检测，了解患者外周血中抗SPAG9自身抗体的表达情况。方法：利用SPAG9重组，确立ELISA检测肿瘤患者血清中抗SPAG9抗体的有效性，从而了解由SPAG9所诱发的患者体液免疫反应。采用的判断标准为：参照组血清中抗SPAG9抗体0D的均值加2倍SD作为阳性。结果：研究的90例肿瘤患者中，血清SPAG9免疫反应总体阳性率为32.3%，肝癌组阳性率为33.3%，肺癌组阳性率为17.9%，其他肿瘤组阳性率为50%，健康对照组为33.3%。结论：SPAG9自身抗体在不同的肿瘤患者外周血中有着不同程度的表达，此次研究具有一定的医学价值。
目的：通過對腫瘤患者血清中抗原9（SPAG9）的自身抗體的檢測，瞭解患者外週血中抗SPAG9自身抗體的錶達情況。方法：利用SPAG9重組，確立ELISA檢測腫瘤患者血清中抗SPAG9抗體的有效性，從而瞭解由SPAG9所誘髮的患者體液免疫反應。採用的判斷標準為：參照組血清中抗SPAG9抗體0D的均值加2倍SD作為暘性。結果：研究的90例腫瘤患者中，血清SPAG9免疫反應總體暘性率為32.3%，肝癌組暘性率為33.3%，肺癌組暘性率為17.9%，其他腫瘤組暘性率為50%，健康對照組為33.3%。結論：SPAG9自身抗體在不同的腫瘤患者外週血中有著不同程度的錶達，此次研究具有一定的醫學價值。
목적：통과대종류환자혈청중항원9（SPAG9）적자신항체적검측，료해환자외주혈중항SPAG9자신항체적표체정황。방법：이용SPAG9중조，학립ELISA검측종류환자혈청중항SPAG9항체적유효성，종이료해유SPAG9소유발적환자체액면역반응。채용적판단표준위：삼조조혈청중항SPAG9항체0D적균치가2배SD작위양성。결과：연구적90례종류환자중，혈청SPAG9면역반응총체양성솔위32.3%，간암조양성솔위33.3%，폐암조양성솔위17.9%，기타종류조양성솔위50%，건강대조조위33.3%。결론：SPAG9자신항체재불동적종류환자외주혈중유착불동정도적표체，차차연구구유일정적의학개치。
Objective: Through the tumor antigen 9 (SPAG9)in serum autoantibodies detection, understanding of peripheral blood in patients with resistant SPAG9 expression of autoantibodies. Methods: Using SPAG9 back together, establish the ELISA detection effectiveness of anti SPAG9 antibody in serum tumor patients, to understand the humoral immune response induced by SPAG9 patients. The judgment standard is:the control group in serum anti SPAG9 antibody 0 d average of 2 times the SD as positive. Results:90 cases of tumor patients, the serum SPAG9 immune response total positive rate was 32.3%, positive rate of liver cancer group was 33.3%, positive rate of lung cancer group was 17.9%, positive rate was 50%, the other tumor group health control group is 33.3%. Conclusion: SPAG9 autoantibodies in different tumor patients have different degree of expression in peripheral blood,the research has some medicinal value.
